ACRS · Insider Trading
Aclaris Therapeutics, Inc.
Every open-market purchase and sale reported by ACRS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Roland Wilhelm Kolbeck | Chief Scientific Officer | MIXED | +23,990 | −$64.40K |
| 2026-06-08 | Maxine Gowen | Director | M | +11,580 | — |
| 2026-06-08 | Vincent Milano | Director | M | +11,580 | — |
| 2026-06-08 | Anand Mehra | Director | M | +11,580 | — |
| 2026-06-08 | William D. Humphries | Director | M | +11,580 | — |
| 2026-06-08 | Christopher P. Molineaux | Director | M | +11,580 | — |
| 2026-06-08 | Andrew N Schiff | Director | M | +11,580 | — |
| 2026-05-05 | Jesse Wayne Hall | Chief Medical Officer | MIXED | +27,045 | −$41.15K |
| 2026-04-27 | Braden Michael Leonard | 10%+ Owner | Sell | −300,000 | −$1.36M |
| 2026-03-03 | Kevin Balthaser | Chief Financial Officer | MIXED | +1,698 | −$1.94K |
| 2026-02-06 | Roland Wilhelm Kolbeck | Chief Scientific Officer | A | +430,600 deriv. | — |
| 2026-02-06 | James Loerop | Chief Business Officer | A | +439,600 deriv. | — |
| 2026-02-06 | Kevin Balthaser | Chief Financial Officer | A | +445,900 deriv. | — |
| 2026-02-06 | Hugh M. Davis | President and COO | A | +432,400 deriv. | — |
| 2026-02-06 | Neal Walker | CEO | A | +1,236,500 deriv. | — |
| 2026-02-06 | Jesse Wayne Hall | Chief Medical Officer | A | +441,400 deriv. | — |
| 2026-02-05 | James Loerop | Chief Business Officer | MIXED | +14,938 | −$20.60K |
| 2026-02-05 | Kevin Balthaser | Chief Financial Officer | MIXED | +15,576 | −$22.38K |
| 2026-02-05 | James Loerop | Chief Business Officer | MIXED | +22,814 | −$37.51K |
| 2026-02-05 | Hugh M. Davis | President and COO | M | +18,675 | — |
| 2026-02-05 | Neal Walker | CEO | MIXED | +44,864 | −$64.58K |
| 2026-02-03 | James Loerop | Chief Business Officer | F | −15,980 | −$39.63K |
| 2026-02-03 | Kevin Balthaser | Chief Financial Officer | MIXED | +9,766 | −$17.49K |
| 2026-02-03 | James Loerop | Chief Business Officer | F | −15,980 | −$39.63K |
| 2026-01-05 | Neal Walker | CEO | MIXED | +19,198 | −$28.66K |
| 2026-01-05 | James Loerop | Chief Business Officer | MIXED | +51,735 | −$120.09K |
| 2026-01-05 | Kevin Balthaser | Chief Financial Officer | MIXED | +67,805 | −$79.62K |
| 2025-12-04 | Hugh M. Davis | President and COO | M | +26,750 | — |
| 2025-08-05 | Roland Wilhelm Kolbeck | Chief Scientific Officer | A | +655,500 deriv. | — |
| 2025-06-09 | Vincent Milano | Director | M | +4,793 | — |
| 2025-06-09 | Christopher P. Molineaux | Director | M | +4,793 | — |
| 2025-06-09 | Anand Mehra | Director | M | +4,793 | — |
| 2025-06-09 | William D. Humphries | Director | M | +4,793 | — |
| 2025-06-09 | Maxine Gowen | Director | M | +4,793 | — |
| 2025-06-09 | Andrew N Schiff | Director | M | +4,793 | — |
| 2025-05-05 | Jesse Wayne Hall | Chief Medical Officer | A | +655,500 deriv. | — |
| 2025-05-05 | Neal Walker | CEO | MIXED | +6,492 | −$4.11K |
| 2025-04-03 | Neal Walker | CEO | MIXED | +6,425 | −$4.50K |
| 2025-03-04 | Neal Walker | CEO | MIXED | +6,189 | −$6.52K |
| 2025-03-04 | Joseph Monahan | Chief Scientific Officer | MIXED | +33,667 | −$54.24K |
| 2025-03-04 | Kevin Balthaser | Chief Financial Officer | MIXED | +2,748 | −$1.45K |
| 2025-02-04 | Joseph Monahan | Chief Scientific Officer | MIXED | +10,933 | −$28.07K |
| 2025-02-04 | Neal Walker | INTERIM CEO | MIXED | +5,908 | −$8.83K |
| 2025-02-04 | Kevin Balthaser | Chief Financial Officer | MIXED | +8,934 | −$14.42K |
| 2025-02-04 | Hugh M. Davis | President and COO | A | +336,300 deriv. | — |
| 2025-02-04 | James Loerop | Chief Business Officer | MIXED | +18,053 | −$38.31K |
| 2025-01-03 | Kevin Balthaser | Chief Financial Officer | MIXED | +56,229 | −$94.79K |
| 2025-01-03 | James Loerop | Chief Business Officer | MIXED | +51,236 | −$100.85K |
| 2025-01-03 | Joseph Monahan | Chief Scientific Officer | MIXED | +49,279 | — |
| 2025-01-03 | Neal Walker | INTERIM CEO | MIXED | +21,180 | −$43.24K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Braden Michael Leonard | 10%+ Owner | 13,950,000 | $52.87M |
| Anand Mehra | Director | 2,637,976 | $10.00M |
| Neal Walker | CEO | 1,562,497 | $5.92M |
| Andrew N Schiff | Director | 459,995 | $1.74M |
| Joseph Monahan | Chief Scientific Officer | 282,188 | $1.07M |
| Kevin Balthaser | Chief Financial Officer | 188,130 | $713.01K |
| James Loerop | Chief Business Officer | 188,008 | $712.55K |
| Christopher P. Molineaux | Director | 69,536 | $263.54K |
| Hugh M. Davis | President and COO | 45,425 | $172.16K |
| William D. Humphries | Director | 45,105 | $170.95K |
| Roland Wilhelm Kolbeck | Chief Scientific Officer | 36,375 | $137.86K |
| Maxine Gowen | Director | 33,334 | $126.34K |
| Vincent Milano | Director | 28,896 | $109.52K |
| Jesse Wayne Hall | Chief Medical Officer | 27,045 | $102.50K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACRS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.